Original Article

Results of a prospective, uncontrolled, single-arm study of 1,351 patients with hiatal hernia operated on exclusively with DeltaMesh hiatal reconstruction over a 10-year period

Eckhard Harry Löhde[1,2*^], Florian Thomas[1,2,3*]

[1]Berlin Centre for Hernia and Reflux Surgery, Parksanatorium Dahlem, Berlin, Germany; [2]Berlin Centre for Hernia and Reflux Surgery, DRK-Klinikum Westend, Berlin, Germany; [3]Clinic for Visceral- and Vascular Surgery, Vivantes Klinikum am Urban, Berlin, Germany

Contributions: (I) Conception and design: EH Löhde; (II) Administrative support: EH Löhde; (III) Provision of study materials or patients: EH Löhde; (IV) Collection and assembly of data: Both authors; (V) Data analysis and interpretation: Both authors; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors.

*The authors affiliated to the 1st affiliation from 2007 to 2013 (presently closed) and the 2nd affiliation from 2014 to 2017.

Correspondence to: Eckhard Harry Löhde, MD. Vordernöring 24, A-9861 Krems, Austria. Email: loehde@mac.com; team@reflux-loehde.de.

Background: Surgical gastroesophageal reflux disease (GERD) therapy is conceptually based on the hypothesis of a deficient lower oesophageal sphincter (LES). Consequently, the focus is on a variety of internal or external oesophageal constrictions, with Nissen and Toupet surgery considered the gold standard. However, clinical outcomes still show wide variations in terms of recurrence and complications and, in particular, there are still unresolved fundamental inconsistencies regarding the function and actual existence of the LES. In this work, a new surgical procedure, laparoscopic oesophagohiatal DeltaMesh enhancement (LOEHDE), was used, based on the emerging pathophysiological suggestion that reflux is instead significantly controlled by a complex cardioesophageal pumping system that decisively depends on the intact hiatal architecture. Accordingly, the surgical focus was solely on the anatomical correct reconstruction of the oesophagohiatal unit without any fundoplication or other conventional anti-reflux measures.

Methods: In a 10-year prospective clinical single arm cohort study from January 2007 to December 2016, all consecutively admitted patients with symptomatic hiatal hernia who met the inclusion criteria underwent the DeltaMesh enhanced oesophagohiatal reconstruction. Patients follow-up was recorded by standardised questionnaires given preoperatively on admission (T0; 43 questions), postoperatively at 1 year (T1; 24 questions) and 5 years (T5; 22 questions). There was no randomisation and no control group, as all patients refused any other form of surgery, especially fundoplication.

Results: A total of 1,351 patients were included and operated on. The follow-up rate was 96% at T0 (1,297/1,351), 68.6% at T1 (927/1,351), and 14.8% at T5 (200/1,351). The Visick score, symptom score, and patient rating significantly improved postoperatively at T1 and T5 ($P<0.0001$) compared with the situation under medical treatment at T0 in all symptom categories: A (reflux, heartburn); B (hoarseness, coughing); C (palpitation, dyspnoea); and D (belching, nausea). Recurrence was observed in 91 of the 1,351 (6.7%) patients. DeltaMesh penetration was observed in the oesophagus (n=2) and stomach (n=3). Mortality (n=1) was 0.07%.

Conclusions: Anatomical reconstruction of the oesophagohiatal unit alone resulted in significant restoration of oesophageal function without fundoplication, confirming the new pathophysiological approach. LOEHDE proved to be a safe, efficient, and standardisable procedure for symptomatic hiatal hernia.

Keywords: Hiatal hernia; reflux surgery; fundoplication; DeltaMesh; laparoscopic oesophagohiatal DeltaMesh

^ ORCID: 0000-0002-2568-8038.

enhancement (LOEHDE)

Received: 07 January 2022; Accepted: 12 June 2022; Published: 25 July 2022.
doi: 10.21037/ls-22-1
View this article at: https://dx.doi.org/10.21037/ls-22-1

Introduction

In recent decades, hiatal hernia, gastroesophageal reflux disease (GERD) and extraoesophageal symptoms have become the most common gastrointestinal disorder worldwide, with a pooled prevalence ranging from about 13% to more than 25% in various countries. The public health dimension may be reflected in the fact that GERD has become the most common gastrointestinal symptom in outpatient diagnosis, with nearly 9 million visits in the United States already in 2009 (1,2).

For years, the therapeutic guidelines for these patients have focused on the administration of proton pump inhibitors (PPIs) in various modalities, although up to 50% of patients report persistence of various symptoms (3-5). The therapeutic gap is widened by the fact that any kind drug therapy can only achieve symptom relief and not a cure, and the unlimited use of medication for decades must be viewed increasingly critically (6-8). Therefore, the therapeutic goal in the future must undoubtedly be successful causal surgical treatment.

This points to the crucial question of what is "causal". The conventional pathophysiological hypothesis considers a diseased and opened LES to be causally responsible for GERD, despite persistent conceptual inconsistencies, which are being tried to be explained by a long list of hypothesised genetic, neurological, hormonal, and environmental cofactors, flaps, valves, and flap valves (9-11). Consequently, the common surgical anti-reflux approach focuses on a variety of therapeutic internal or external oesophageal strictures such as gastric wrapping from 90° to 360°, oesophageal wall destruction and scarring, magnetic closure, division of short gastric vessels, and all forms of mesh implantation in addition (12-18).

However, even after decades, there is still no conceptual breakthrough, fundoplication, with all its shortcomings, is widely accepted as the surgical "gold standard" for anti-reflux therapy, and practically gastroenterologists and general practitioners still consider surgery as the last option, not least because of the rather limited good surgical results in their patients.

New MRI data may open up a crucial new pathophysiologic concept. It is assumed that reflux control does not occur through a hypothetical LES, but through a complex cardio-oesophago-diaphragmatic interacting system (CODIS) that is determined by a continuous downward rollout movement of the heart onto the ventral wall of the oesophagus, which is more or less only passively involved in the system. However, the position of the oesophagus and the three-dimensional hiatal architecture proved to be crucial but vulnerable to the functioning of this system (19). Based on these new findings, the technique of laparoscopic oesophagohiatal DeltaMesh enhancement (LOEHDE) was developed, which focuses exclusively on the correct anatomical reconstruction of the oesophagohiatal unit. Fundoplication or other anti-reflux procedures were strictly omitted in all patients. For long-term stabilisation of the hiatus, a new three-dimensional DeltaMesh was applied, which is specifically designed to meet the special requirements of a destructed hiatus and efficiently neutralises the axial and tensile acting forces. We present the following article in accordance with the STROBE reporting checklist (available at https://ls.amegroups.com/article/view/10.21037/ls-22-1/rc).

Methods

Study design

This study was conducted as a prospective uncontrolled single-arm cohort study over a 10-year period, from January 2007 to December 2016. All patients consecutively admitted with symptomatic type I–IV hiatal hernias from Germany and other EU countries who met the inclusion criteria underwent surgery according to LOEHDE using DeltaMesh in all cases. No other anti-reflux surgery was performed. Surgeries were carried out by two surgeons and successively in two hospitals in Berlin, Germany: the Parksanatorium Dahlem, D-14199 (2007-2013, presently closed) and the DRK-Klinikum Westend, D-14050 (2014-2017). This study had no control group and was not randomised, as all patients specifically wanted to be operated

on with LOEHDE only without fundoplication or other techniques. This was respected and, for ethical reasons, patients were not persuaded to undergo fundoplication instead.

Ethics approval

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Commission of the Ärztekammer Berlin, Friedrichstr. 16, D-10969 Berlin, Germany (approval number: Eth-56/20), and listed in the German Clinical Trial Register DRKS (registered number: DRKS00024357) being accepted by the WHO and the International Committee of Medical Journal Editors (ICMJE). All included patients specifically asked for LOEHDE. Nevertheless, they were extensively informed about the common fundoplication being the accepted "gold standard" in anti-reflux surgery. All patients provided signed informed consent, agreed on the 5-year follow-up, consented to further scientific utilisation of their anonymised data, and were instructed to keep close contact in case of any irregularity.

Inclusion criteria

All type I–IV hiatal hernias were included. The definition of "symptomatic" was based on the following four symptom categories: (A) fluid reflux such as heartburn, bending forward reflux, nocturnal cough, and a need for diet; (B) aerosol reflux such as hoarseness, throat clearing, globus sensation, sinus swelling, and posterior laryngitis; (C) core symptoms such as chest pain, feeling of incarceration, cardiac sensations, back pain, and dyspnoea; (D) functional disorders such as dysphagia, belching, fast eating, and bloating.

The inclusion criteria for the entire study period were as follows: (I) age ≥15 years (mandatory); (II) increasing symptoms in categories A, B, C, and D with significant impairment of daily life (mandatory); (III) endoscopic findings of an incompetent cardia or hiatal hernia, irrespective of size (mandatory) (IV) oesophagitis with a Savary–Miller grade ≥2 or Los Angeles classification grade ≥B (20,21); (V) histopathological findings of oesophagitis or Barrett's metaplasia or dysplasia; (VI) ineffectiveness of PPIs or adverse effects; and (VII) pathological findings of pH measurement, manometry, X-ray contrast swallow evaluation, computed tomography (CT), or magnetic resonance imaging (MRI). Patient's physical status was classified by the physical status classification system of the American Society of Anesthesiologists (ASA) (22).

The exclusion criteria were age <15 years, suspected achalasia or malignancy, comorbidities that did not justify surgical treatment, and a doubt about diagnosis.

Patient-reported outcome

Basic data were collected from the patient records. Outcome data were collected by means of questionnaires through direct contact with patients by post, mail or telephone at 4 observation time points: (I) T0Med– = preoperative status, if PPIs were not administered; (II) T0Med+ = preoperative status, if PPIs were administered; (III) T1 = postoperative status, 1 year postoperatively without PPIs; (IV) T5 = postoperative status, 5 years postoperatively without PPIs. Forty-three standardised and open questions were asked preoperatively at T0Med– and T0Med+, and 24 and 22 questions were asked postoperatively at T1 and T5, respectively. The questionnaires contained various questions on symptoms, medical history, nutrition, quality of life, medication, examinations performed, postoperative problems, and therapy evaluation (Appendixes 1-3).

The following scores were integrated:

- The symptom score was redesigned based on patients' empirically frequently reported complaints to specifically detail the outcome of A-D classified symptoms postoperatively. The symptom score has not yet been validated. It was recorded at all four observation points on a scale of 0–4, reflecting "well-being" with regard to a specific symptom at a high score: 0 = complaints all the time (daily); 1 = often (2–3×/week); 2 = on and off (1×/week); 3 = rarely (1×/month); and 4 = never (does not occur). These time intervals were chosen to help patients describe the frequency of their complaints in a structured and comparable way (Appendixes 1-3).
- The Visick score I-IV, which is commonly used to assess the patient's general well-being, was recorded at all four observation time points, reflecting "well-being" at a low score: I = no complaints; II = mild complaints relieved by care and doctor visits are rare; III = moderate complaints not relieved by care and doctor visits are often; IV = no improvement (Appendixes 1-3).
- The patient rating score was introduced to capture the patients assessment of surgical success compared to the recalled effectiveness of PPI treatment preoperatively. The assessment was made at T1 and



Figure 1 DeltaMesh diagonal front view. At the base, in the area of the strongest tensile forces, the largest surface area of the wings is kept ready for muscle integration. The three-dimensional structure of the T-profile results from the vertically rising centrefold.



Figure 2 DeltaMesh cross-section. (A) The wings are placed retrocrurally with the C in the midline. The suture is threaded in the base. (B) During closure, the suture presses both crura into its compartments of the T-profile and ensures tight integration of muscle and mesh. C, centrefold.

T5 on a scale of 1–5, reflecting "great success" at a low score: 1 = excellent; 2 = good; 3 = satisfying; 4 = sufficient; and 5 = poor. The patients' ratings were based on the German school grading system to help patients classify their rating in a familiar system (Appendixes 2,3).

- Food intolerances were recorded at T0, T1 and T5 to capture their progression with respect to the empirically most commonly reported critical drinks such as white wine, sparkling wine, red wine, fizzy drinks, fruit juices, and coffee, as well as food such as sweets, cakes, chocolate, and tomatoes (Appendixes 1-3).

DeltaMesh

The DeltaMesh is a V-shaped, 30×40×11 mm, three-dimensional polyvinylidene fluoride mesh designed to target the specific anatomy of the hiatus. The two wings and the vertical lengthwise rising central fold form two compartments that adapt the principle of a three-dimensional T-profile (*Figure 1*). This allows for tight intermuscular bi-angular embedding of the crura. The DeltaMesh is designed for the retroperitoneal position, and the contact is almost exclusively limited to the crura. The DeltaMesh does not require additional fixation but is integrated into regular hiatus sutures (*Figure 2*). (DynaMesh®-DELTA by FEG Textiltechnik Forschungs- und Entwicklungsgesellschaft mbH, Aachen, Germany, and approved in Germany by TÜV Süd, referring to the guidelines of the European Union 93/42/EWG and 2007/47/EG, certificate number: G1 107055 0001 Rev.02. The DeltaMesh has not yet been approved by the US Food and Drug Administration in the USA).

LOEHDE

The procedure involved a 5-trocar technique (1×10 mm; 1×11 mm; 3×5 mm) with the patient in the reverse Trendelenburg position and insertion of a 30 Ch. gastric tube. First, an incision was made in the minor omentum and ventral peritoneal lining of the hiatus. The oesophagus and the posterior vagal nerve branch were exposed and the herniated organs were predominantly repositioned without resection of the hernia sac. The shortened dorsal meso-oesophagus was released to allow for the necessary oesophagus ascent, and the posterior sides of both crura were exposed to ensure free spreading of the DeltaMesh



Figure 3 Schematic illustration of hiatus closure with DeltaMesh. (A) Measurement of the hiatal defect after oesophageal repositioning (double arrow). (B) Position of the adapted DeltaMesh with the base up and the tip down. The wings are unfolded retrocrurally and the centrefold rises in the midline (arrows). (C) Reverse closure of the hiatus, starting with the upper suture ①. Completion of the closure by the second suture ②, ensuring homogeneous longitudinal expansion of the DeltaMesh.

wings retrocrurally.

The left hiatal circumference was dissected while preserving the anterior vagal nerve branch. Finally, the oesophagus was relocated to its correct ventral position. Hernia size was estimated as the distance between the dorsal oesophageal wall and posterior confluence of the crura after complete repositioning. The hiatus was closed in a reverse closure procedure:

For this, the crucial first suture (0-Prolene 0.9m, CT-2 Plus; PROLENE™, Ethicon® Endo-Surgery Inc., USA) was placed directly below the oesophagus, taking 8–10 mm of the left crus. After extracorporeal threading of the DeltaMesh base the right crus was correspondingly grasped in a horizontal line. The hiatus was firmly closed around the oesophagus with an immediate tight locking suture using an extracorporeal knot technique under tension allowing a smooth run of the controlling 30 Ch gastric tube. Adequate longitudinal expansion of the DeltaMesh and complete hiatus closure were ensured by one or two downward sutures. Additional DeltaMesh fixation or anti-reflux procedures were not required (*Figure 3*).

In cases of recurrence after the Nissen/Toupet procedure or other procedures, fundoplication was reset as far as possible occasionally with fundus resection, if necessary, followed by LOEHDE. In cases of recurrence after LOEHDE, the procedure was repeated with an additional small DeltaMesh, leaving the first one in place. Fundoplication or other procedures were not performed in any case.

Recurrence

Recurrence was primarily defined as patients complaining of persistent symptoms, requiring PPIs and dietary changes for relief, and ruling out of other causes. Clinical suspicion was always confirmed by endoscopy, and in cases of doubt, by pH measurement or other methods. Each patient was offered a re-do surgery.

Statistical analysis

Data from questionnaires were transferred to Excel and consecutively analysed using SPSS® (IBM SPSS Statistics, RRID: SCR_019096 version, Armonk, NY, USA) and R version 3.5.0. (R Project for Statistical Computing, RRID: SCR_001905, R Core Team 2018, R Foundation for Statistical Computing, Vienna, Austria, URL: http://www.R-project.org.) Regression models were fitted using the ordinal [Christensen RHB (2019), Ordinal-Regression Models for Ordinal Data, R package version 2019.12-10. https://CRAN.R-project.org/] and brms packages (23).

Data are presented as standard descriptive statistics including frequencies, proportions, means, medians, and quartiles. The Visick score, symptom score, and patient ratings were analysed using hierarchical ordered logistic regression models. Separate models were constructed

for each score type. Fixed effects (indicator variables) for measurement occasions were included in all models, and a therapy indicator was included in the model for patient rating. Treatment-time interaction was initially tested and omitted from the final model based on a likelihood ratio test of the interaction term. All models included random intercepts grouped by patients.

To test the overall time effect on symptoms, a model including all symptom types was used, with random effects grouped by symptom type. Random effects for individuals and symptom types were assumed to be independent. Likelihood ratio tests were employed to test for fixed effects. Food intolerance was coded as a dichotomous variable and modelled using a mixed-effects logistic regression model with fixed effects for measurement occasions and random intercepts grouped by individuals and food types, respectively. The likelihood ratio test was used to test the overall differences across measurement occasions (T0Med+, T1, and T5).

Incomplete and missing data are marked as not available in the graphical presentations in figures and tables of frequency in the supplementary.

Results

Patient characteristics

A total of 1,351 patients were included, of which 1303 (96.4%) had primary hernia and 48 (3.6%) had recurrence or re-recurrence after preceding surgery using Nissen (n=22), Toupet (n=19), Thal (n=2), or other procedures (n=5), partially re-enforced by onlay mesh. All I–IV types of hernias were included but not differentiated in detail, with type I clearly predominating. The patients were 55.9% male and 44.1% female, with a median age of 45 years (range, 15–83 years). Disease persisted <5 years in 50.1% of patients, and 6–10, 11–15, 16–20, and >21 years in 25.7%, 11.2%, 7.3% and 5.8% of patients, respectively.

The regular PPI medication used by 97.4% of patients were pantoprazole, omeprazole, esomeprazole, and rabeprazole, in descending order. The diagnostic measures on the patients by their doctors included stress or 24-h electrocardiography (41.6%), X-ray contrast swallow evaluation (36.5%), MRI/CT (28.8%), and cardiac catheter examination (6.4%). Patients had estimated 10 visits (median, 1–50) to their general practitioner and three gastroscopies (median, 1–12) before surgery. The patients reported 4555 doctors' recommendations for further therapy. Continued medication, changes in diet, increase in PPI dosage, changes in general behaviour, or change in type of medication were recommended 1,143, 731, 686, 576, and 369 times, respectively (n=3,505). 585 recommendations considered an operation, 465 were explicitly against it. 97.1% patients were classified as ASA1 or ASA2, 2.9% as ASA3.

The patients were operated by two surgeons and all surgeries were completed laparoscopically. DeltaMesh enhancement was successful irrespective of the hernia size or previous surgery. The hernia size was 1–2 cm in 5.1% of 451 patients and 2–4, 4–6, and 6–8 cm in 69.2%, 22.2%, and 3.5%, respectively. An enlarged DeltaMesh was used when required. The number of hiatal hernia surgeries per year increased from 73 in 2007 to 196 in 2016.

The follow-up rate of the 1,351 operated patients within the 10-year period from January 2007 to December 2016 was 96% at T0 (1,297/1,351), 68.6% at T1 (927/1,351), and 14.8% at T5 (200/1,351).

Due to the end of the study after 10 years, observation point T1 could only be reached by 1,287 patients and the questionnaire response rate was 72% (927/1,287). Observation point T5 could be reached by 529 patients and the questionnaire response rate was 37.8% (200/529). The continuous follow-up of the patients ended in December 2019.

Patient-reported outcomes

Symptom score

A comparison of T0Med– and T0Med+ confirmed that median symptom scores improved by one point from 1 to 2 or 2 to 3 with PPI treatment for heartburn, nightly cough attacks, belching, bloating, nausea, chest pain, palpitation, and dyspnoe, indicating relief but not cure. Median scores for other factors, such as volume reflux, sore throat, dysphagia, and hoarseness, remained largely the same.

The comparison of optimised PPI treatment (T0Med+) *vs.* LOEHDE showed increased scores at T1 and T5 for all symptoms except dysphagia (*Figure 4*). The symptom score increased from 2 to 4 after surgery especially for the main complaints such as heartburn, volume reflux, hoarseness, and sore throat. An additional improvement of the symptom score from 3 to 4 was seen for palpitation, dyspnoea, cough attacks at night, and nausea. Only minor improvements from 2 to 3 were seen for belching, bloating, and chest pain. The low response rate for T5 must be considered. The outcome was comprehensively confirmed by the proportion and distribution of symptom scoring values (Table S1,



Figure 4 Symptom scores at T0Med–, T0Med+, T1, and T5. Compared to the situation without PPI medication (T0Med–), PPI medication (T0Med+) provided some improvement, especially for heartburn. After LOEHDE at T1 and T5, the highest symptom scores were achieved in almost all categories. Dots represent medians and triangles represent means. Size of the mark corresponds to the number of patients (N). PPI, proton pump inhibitor; LOEHDE, laparoscopic oesophagohiatal DeltaMesh enhancement.

Figure S1). The test of the overall time effect on symptom scores in the regression model suggested differences in symptom scores across the different time points (Likelihood ratio statistic: 5262; df: 2; $P=2.2\times10^{-16}$ or $P<0.0001$). Based on hierarchical ordered logistic regression, a joint model could be generated for the prediction of symptom scores at T1 and T5, thus predicting the probability of the postoperative course and probable scores for each symptom (data not shown).

Food intolerance

The comparison of T0Med– and T0Med+ showed that the complaints triggered by critical drinks and foods were only slightly alleviated by PPI. Patients still had to adhere to a diet. In contrast, after surgery at T1 and T5, all critical foods were significantly better tolerated. (*Figure 5*). (LR test: 3778, df: 2, $P<2\times10^{-16}$ or $P<0.0001$). Frequencies and missing data are shown in the supplement (Table S2).

Visick score

At T0Med+ preoperatively, most patients reported "moderate complaints and frequent doctor visits" despite optimised PPI therapy reflecting the median Visick score of III (range, I–IV). Conversely, at T1 and T5, patients predominantly attributed their improved condition to the median Visick score of II (range, I–IV). The low response



Figure 5 Preoperatively, critical food was poorly tolerated without treatment (T0Med–). PPI medication showed an improvement especially for heartburn, while other complaints were only slightly alleviated (T0Med+). After LOEHDE at T1 and T5, there were almost no restrictions for the patients. PPI, proton pump inhibitor; LOEHDE, laparoscopic oesophagohiatal DeltaMesh enhancement.

rate for T5 must be considered (*Figure 6*). (LR test: 1329, df: 2, $P<2.2\times10^{-16}$ or P<0.0001). This was comprehensively confirmed by the proportion of Visick scoring values and frequencies (Figure S2, Table S3).

Patient rating

Retrospectively, PPI treatment was concordantly rated poorly at T1 and T5 with the median score of 5 (range, 1–5). Inversely, LOEHDE was rated excellent with the median score of 1 at both T1 and T5 (range, 1–5). The low response rate for T5 must be considered (*Figure 7*). (LR test: 1963, $P<2.2\times10^{-16}$ or P<0.0001). This assessment was confirmed by the proportion of scoring values and frequencies (Figure S3, Table S4).

Correspondingly, the question at T1 as to whether patients would re-take their decision to have surgery was answered as definitely, probably yes, probably no, and definitely no, by 82.3%, 13.2%, 3.6%, and 0.9% of patients (n=863), respectively.

Clinical observation

The regular postoperative course was that symptoms such as heartburn, volume reflux, chest tightness, and dyspnoea should disappear immediately. Heart symptoms and respiratory symptoms such as hoarseness and sore throat subsided within 1 week. Regular food intake was achieved after 1–3 weeks. Burping was generally not a problem for patients postoperatively. PPI medication was discontinued immediately or gradually. The ability to vomit was not explicitly asked in the questionnaires, but was casually confirmed by a few patients. However, patients did not



Figure 6 Visick scores at T0Med+, T1, and T5. Despite optimized PPI treatment, patients reported moderate complaints with frequent doctor visits with a median Visick score of III (range, I–IV). After LOEHDE at T1 and T5, the score was downgraded to mild complaints and a median Visick score of II (range, I–IV). Dots represent median and triangles represent means. Size of the mark corresponds to the number of patients (N). PPI, proton pump inhibitor; LOEHDE, laparoscopic oesophagohiatal DeltaMesh enhancement.



Figure 7 Patient rating of treatment efficacy in hindsight at T1 and T5. With the experience of both therapies, patients rated the PPI treatment as sufficient and poor with the median of 5 (range, 1–5), while LOEHDE was rated as good and excellent with a median score of 1 (range, 1–5). Dots represent medians and triangles represent means. Size of the mark corresponds to the number of patients. PPI, proton pump inhibitor; LOEHDE, laparoscopic oesophagohiatal DeltaMesh enhancement.

mention problems in the general questions at T1 and T5, nor did they contact the team in any other way.

Recurrence

Recurrences were continuously recorded and observed in 91/1,351 (6.7%) patients during the observation period from January 2007 to December 2016. Recurrence occurred primarily within the first 2 years (58%) postoperatively and decreased continuously in the following years (*Figure 8*). During reoperation, the DeltaMesh proved to be firmly ingrown in the hiatus, but the ventral area around the oesophagus showed hiatal instability. All patients experienced re-displacement of the oesophagus and additional DeltaMesh enhancement, with the first one remaining in place. No procedure such as fundoplication or other was performed.

The recurrence rates of LOEHDE for primary hernia and fundoplication were 6.7% (87/1,303) and 8.3% (4/48), respectively. Among the 91 patients with recurrence, 19 continued conservative treatment, and 72 underwent re-do LOEHDE. Re-recurrence after re-do LOEHDE was detected in 5/72 (6.9%) of patients (*Table 1*).



Figure 8 Time course of recurrences (n=91). More than 50% of the recurrences after LOEHDE emerged within the first 2 years followed by increasing long-term stability. LOEHDE, laparoscopic oesophagohiatal DeltaMesh enhancement.

Six women reported their pregnancy after surgery, of which five had no problems in and after pregnancy and one had a recurrence after the second birth 6 years postoperatively and was operated on again.

Morbidity and mortality

Full recovery from surgery was retrospectively reported

Table 1 Recurrence rate after LOEHDE

	LOEHDE operation, n	Recurrence diagnosed, n (%)	Recurrence operated, n	Re-recurrence diagnosed, n (%)
Total	1,351	91 (6.7)	72	5 (6.9)
On primary hernia	1,303	87 (6.7)	68	4 (5.9)
On fundoplication recurrence	48	4 (8.3)	4	1 (25.0)

LOEHDE, laparoscopic oesophagohiatal DeltaMesh enhancement.

at T1 after a median of 4 weeks (range, 1–32 weeks). Cumulatively, 22.4% of patients felt recovered after 3 weeks, 80% after 6 weeks, 90.9% after 9 weeks, and 97.5% after 12 weeks (n=835).

Major postoperative complications developed in 62/1,351 (4.6%) patients, of whom 46 (74.2%) had complications due to re-surgery and 16 (25.8%) required other conservative care or endoscopic intervention. The primary reason for re-surgery was dysphagia (35 patients). In 26 patients re-surgery was performed within the first 3 weeks postoperatively at day 6 (median, range day 1–21). Nine patients were initially treated conservatively, but underwent re-surgery 5 months postoperatively (median, month 1–12).

Other patients showed a subhepatic abscess that did not affect the DeltaMesh (one patient), a gastric perforation that did not affect the DeltaMesh (one patient), severe fungal sepsis of unknown origin with DeltaMesh removal as a precaution (one patient), and haemorrhage (two patients). Mortality was observed in one (0.07%) of the 1,351 patients due to poorly managed bleeding complications not associated with the DeltaMesh.

DeltaMesh-associated complications emerged in five patients. In two patients, the DeltaMesh penetrated the distal oesophagus (22 and 26 months after surgery), causing pain and dysphagia. In these two patients, the DeltaMesh was removed by endoscopy, and the defect healed without further complications. In three patients, asymptomatic penetration of a DeltaMesh edge into the stomach was incidentally observed by control endoscopy after a mean of 48.3 months postoperatively with no need for further intervention to date. Notably, DeltaMesh penetration occurred exclusively in patients who had already undergone one or more Nissen or other surgeries with severe hiatal scarring.

Discussion

The study design has definite methodological limitations. First, no control group was formed because the patients who came refused fundoplication or any operation other than the LOEHDE procedure mostly due to critical patient reports on the internet or opposition from their doctors. Although this methodological deficiency could not be avoided, it clearly forces caution in the interpretation of these data.

Second, the origin of the patients from different parts of Germany and the EU, different health insurance companies, cost structures, lack of interest or the refusal of treating doctors to schedule further examinations without medical indication prevented a standardised follow-up, for example, by pH-metrics and endoscopy. This form of follow-up could only be carried out in patients with Barrett's metaplasia. However, the carefully conducted analysis of the patient reports proved to be highly informative and clearly outperformed apparative diagnostics, especially in assessing outcome, detecting recurrence, and deciding whether to operate again (24,25).

In this context, it should be noted that, surprisingly, many of the preoperative reports of the patients admitted from various clinics and specialists proved to be unreliable, incomplete, and even false compared to the intraoperative findings including endoscopy (26,27). For the patients, this frustrating diagnostic workup, combined with the persistent complaints, means increasing exhaustion, which is answered by doctors prescribing antidepressants or admitting them to psychiatric institutions (28,29). The observed diagnostic misjudgements raise the fundamental question of how a methodologically reliable and comparable pre- and postoperative diagnostic assessment can be achieved for hiatal hernia patients.

Third, the score systems used are criticisable. The Visick score is considered an established tool for evaluating surgical success in anti-reflux therapy (30). However, the Visick score is undifferentiated and only represents the severity of general complaints in a grossly simplified way (31).

The symptom score was newly invented and not

validated. The redesign of the symptom score was necessary because the aim was not only to measure the outcomes of well-being, quality of life, reflux and recurrence, but also to determine in detail which of the various preoperative symptoms of categories A-D and to what extent can be influenced by the reconstruction of the oesophagohiatal unit. This should make it possible to infer the detailed functions of the oesophagus that are directly related to the hiatal architecture and CODIS. This approach for this study is not adequately covered by common scores such as Visick score, Quality-of-life in Reflux and Dypepsia (QOLRAD), Gastrointestinal Symptom Rating scale (GSRS), SF-36 Health Survey, or GERD–HRQL (32-35).

The patient rating score must not be equated with an objective success of the operation. Nevertheless, it is important for the evaluation of this new surgical procedure to know whether or not patients are still basically satisfied with the operation performed, even years later (36).

Forth, the common guidelines for comprehensive preoperative diagnostics such as upper endoscopy, barium oesophagram, pH testing, and manometry, oropharyngeal pH testing, multichannel, and intraluminal impedance, in the context of patient selection for fundoplication, were not fully adopted in the indication concept of this study (37). However, these procedures serve to gain preoperative insights into the multifactorial pathogenesis of reflux disease and the disturbed functionality of the oesophagus in order to decide, whether and how fundoplication should be tailored to the individual's oesophagus function against the background of known side effects such as gas bloating, severe dysphagia, difficult belching, impossibility of vomiting, or whether these risks should not be taken at all.

It should be noted, however, that LOEHDE is a completely different surgical approach of sole anatomic reconstruction without wrapping, constriction or even suturing of the oesophagus. Since no definite histomorphological disease of the oesophagus was ever detectable, but only functional disturbances of the system, the oesophagus should be considered a priori as a healthy organ even in reflux patients.

This points to the central point of this study, which shows that stable repositioning of the oesophagus in the oesophagohiatal unit alone appears to restore all the various impaired functions. This clinically found interdependence of oesophagus position and function seems to confirm a new perspective on the oesophagus. These results are in full accordance with recent findings from cine-MRI and X-ray contrast swallow studies that the oesophagus might be a passive part of an interacting cardioesophageal peristaltic pump system. Data show the heart acting as the central pump that triggers rapid clearance and functional reflux control by a downward rollout impulse along the oesophagus, referred to CODIS (19). Correspondingly, data showed that the function of the system crucially depends on the exact position of the oesophagus in the three-dimensional set-up of the system, which is controlled by the oesophagohiatal unit (38). In this respect, endosonography of the oesophagus may become a promising diagnostic tool in future. These new pathophysiological findings seem to explain the successful recovery of the systems functionality after LOEHDE, which in fact focuses exclusively on the required three-dimensional repositioning of the oesophagus.

This observation clearly contradicts the common hypothesis of a diseased LES or entire oesophagus in reflux patients. It is also in marked contrast to studies showing that hiatoplasty alone is usually not sufficient to predictably cure patients without fundoplication (39). However, it must be considered that the usual surgical approach to hiatoplasty in the fundoplication procedure is only to close a hole in the diaphragm and not to restore function by reconstructing the crucial position of the oesophagus. Therefore, this part is commonly underestimated, and a variety of different techniques are used, such as dorsal, ventral, or both sutures, sutures too close together, jeopardising crural circulation, and still intracorporeal knotting techniques, which are not suitable to overcome the increasing traction forces in the upper part of the hiatus, so that just crura narrowing is often considered sufficient.

Several randomised trials that specifically dealt with crural closure have reported poor methodological quality. Studies have shown that a detailed technical description of this important surgical part is completely omitted from the methodology or is often casually dismissed as a mere routine posterior hiatus repair. However, if described at all, the crura are only approximated, leaving gaps as wide as 1–2 cm, so that the oesophagus may remain unstable in an incorrect dislocated position and the pathological opening between the abdominal and thoracic compartment persists (39-41). This procedure is clearly different from the stable reconstruction of the oesophagohiatal unit targeted by LOEHDE.

Undoubtedly, fundoplication as the common "gold standard" in reflux surgery can restore reflux control. The success of the fundoplication procedure has generally been attributed to gastric wrapping for the external support of the hypothetical LES. Surprisingly, however, the data do

not show major differences in outcomes between 90°, 180°, 270°, and 360° fundoplication, which would undoubtedly be expected with such fundamentally different surgical procedures (42-44).

In view of the identified crucial importance of oesophageal ventralisation in the hiatus, the remarkable success of these various forms of fundoplication could be explained by the fact that the dorsal pull-through of the gastric cushion eventually pushes the oesophagus into its required elevated position in the hiatus, resulting in healing despite a possibly inadequate hiatoplasty. In this respect, a 90° or 360° wrapping should indeed be of secondary importance as demonstrated, rather than the actual volume of the gastric cushion, which in principle might give some more advantage in Nissen and Toupet procedures.

This suggests gastric wrapping thus seems to be more important to compensate for a potential inadequate hiatus reconstruction. Therefore, in the case of an anatomically correct rearrangement of the oesophagus from the outset, as in LOEHDE, fundoplication should be superfluous. Accordingly, the complete release of the cuff had no negative effect on any of the 48 operated fundoplication recurrences when followed by stable oesophageal repositioning according to LOEHDE and hiatal instability was proved to be the most important factor and main cause of recurrency in the other studies as well (45-47).

In this context, the unresolved question raises of why different types of hernia can cause different symptoms so that even different therapeutic approaches are discussed (48,49). With regard to the pathophysiological concept of CODIS, axial displacement of the stomach in type I hernia can easily compromise the cardiooesophageal junction, resulting in loss of reflux control. However, when the stomach slides strictly para-oesophageal in particular dorsal to the oesophagus, without pushing the oesophagus out of the cardiac pressure zone as in type II hiatal hernia, Patients have various symptoms such as incarceration, pain, dyspnoea, etc., but little or no symptoms related to CODIS function, e.g., reflux control. CODIS is still functional.

However, if the cardioesophageal junction becomes increasingly compromised, as in a type III mixed hiatal hernia, there will inevitably be a loss of reflux control as well.

The different symptoms of the different hernia types may therefore be explained by their different impact on CODIS. The correct anatomical reconstruction by LOEHDE therefore healed all patients in the same way regardless of the hernia type. However, the exact distribution of hernia types was not routinely recorded in this study, not least because in practice the pre- and intraoperative distinction between type I and III or type II and III in particular is imprecise. Para-oesophageal hernia was not found to be a risk factor for recurrence or other complications.

To achieve the crucial goal of long-term stability of the oesophagohiatal unit, the DeltaMesh was designed specifically for the requirements of a destructed hiatus (Appendix 4). The laparoscopic application of DeltaMesh has proven to be simple, effective and standardisable and significantly facilitates and accelerates hiatus closure. However, in this study, a total of 91/1,351 (6.7%) patients had a recurrence, including all hernia sizes, re-do surgeries, and postoperative risks in the everyday life of patients (*Table 1*). The recurrence rate during continuous follow-up increased to 7.2%, with seven additional recurrences observed between January 2017 and December 2019. Recurrence after LOEHDE was associated with renewed hiatus weakness and displacement around the oesophagus, while the DeltaMesh was still firmly integrated downwards into the crura in all patients. Re-LOEHDE in the weakened area caused the symptoms to disappear again.

Often no specific reason for the recurrence could be identified. However, risk factors were found to be long-lasting coughing, strong spontaneous pressing in the anaesthetic recovery phase during surgery, hiatus anatomy and the angle of crura insertion in the diaphragm, surgical misjudgement during reconstruction, impaired crura innervation presumably due to transcrural sutures, and crude postoperative endoscopy. Risk factors such as obesity, scoliosis, type of hernia, and heredity did not play a role in the emergence of recurrence.

It is still too early to examine the comparability of these results in the literature, given the wide range of different types of operations, major methodological differences in terms of indication, surgical technique, and definition and detection of recurrence, or lack of such information (41). Therefore, a methodologically standardised study protocol for hiatal hernias still seems necessary for reliable significance and comparability (36,50).

However, it is worth mentioning that re-operation after a previous fundoplication showed a comparable low recurrence rate of 8.3%. This success and the absence of intraoperative complications are probably due to the surgical focus being solely on re-stabilising the oesophagohiatal unit rather than risking re-fundoplication or other modified solutions (51-54).

As the worst DeltaMesh-associated complication, five patients experienced the penetration of the DeltaMesh into

hollow organs even though the DeltaMesh was conceptually designed exclusively for extra-abdominal use to avoid such risks (55-57). Intervention was necessary in two cases of oesophagus penetration. The small size of the DeltaMesh clearly facilitated complication management and allowed purely endoscopic mesh removal and defect closure with fibrin glue. DeltaMesh penetration was an observed but rare complication that occurred only in patients after re-do or re-re-do surgeries with a heavily scarred intraoperative situation. These risks seemed acceptable to justify DeltaMesh use to improve the long-term results in hiatal hernia patients. However, the low follow-up rate of 14.8% and questionnaire response rate of 37.8% at T5 does not allow a conclusive statement.

Conclusions

These clinical data from 1,351 patients treated with LOEHDE and the ongoing surgical experience demonstrate that reconstruction of the three-dimensional architecture of the oesophagohiatal unit alone can predictably restore reflux control and other impaired oesophageal functions. These data confirm the new pathophysiological finding that dysfunction of the oesophagus is due to its malposition in CODIS. The correct three-dimensional reconstruction of the oesophagohiatal unit thus seems to be the key to restoring all functions of the system. These results clearly contradict the common LES hypothesis.

The use of the DeltaMesh has proven to be a safe, efficient, and time-saving surgical tool for stable hiatus closure. These new findings can hopefully open a new approach to the pathophysiology of oesophageal function and new ways for diagnostics and therapy in the future.

Acknowledgments

We would like to acknowledge the following: Dipl.-Ing. Stefan Schneemelcher (FEG), Dr. Philipp Schuster (FEG), and Manfred Grewe (FEG) (DeltaMesh development and graphic support); Dr. András P. Keszei (statistical analysis); Dani Gattermann and Dao Brömert (data collection and operational assistance) and Editage (professional publication support).

Funding: None.

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://ls.amegroups.com/article/view/10.21037/ls-22-1/rc

Data Sharing Statement: Available at https://ls.amegroups.com/article/view/10.21037/ls-22-1/dss

Peer Review File: Available at https://ls.amegroups.com/article/view/10.21037/ls-22-1/prf

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://ls.amegroups.com/article/view/10.21037/ls-22-1/coif). EHL reports that he (inventor) and FEG Textiltechnik, Forschungs- und Entwicklungsgesellschaft mbH, Aachen, Germany, hold a patent with Global Patent Index EP 2848230 B1 for the DeltaMesh. FEG provided support in statistics work-up and graphic design for this paper only. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any parts of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Commission of the Ärztekammer Berlin, Friedrichstr. 16, D-10969 Berlin, Germany (approval number: Eth-56/20), and listed in the German Clinical Trial Register DRKS (registered number: DRKS00024357) being accepted by the WHO and the International Committee of Medical Journal Editors (ICMJE). Written informed consent was obtained from the patients for publication.

References

1. Richter JE, Rubenstein JH. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology 2018;154:267-76.

2. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-1187.e3.
3. Hillman L, Yadlapati R, Whitsett M, et al. Review of antireflux procedures for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus 2017;30:1-14.
4. Delshad SD, Almario CV, Chey WD, et al. Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology 2020;158:1250-1261.e2.
5. Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease: A Review. JAMA 2020;324:2536-47.
6. Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology 2017;153:35-48.
7. Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open 2017;7:e017739.
8. Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med 2016;176:238-46.
9. Herregods TV, Bredenoord AJ, Smout AJ. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era. Neurogastroenterol Motil 2015;27:1202-13.
10. Mikami DJ, Murayama KM. Physiology and pathogenesis of gastroesophageal reflux disease. Surg Clin North Am 2015;95:515-25.
11. Boeckxstaens G, El-Serag HB, Smout AJ, et al. Symptomatic reflux disease: the present, the past and the future. Gut 2014;63:1185-93.
12. Du X, Hu Z, Yan C, et al. A meta-analysis of long follow-up outcomes of laparoscopic Nissen (total) versus Toupet (270°) fundoplication for gastro-esophageal reflux disease based on randomized controlled trials in adults. BMC Gastroenterol 2016;16:88.
13. Kethman W, Hawn M. New Approaches to Gastroesophageal Reflux Disease. J Gastrointest Surg 2017;21:1544-52.
14. Das B, Reddy M, Khan OA. Is the Stretta procedure as effective as the best medical and surgical treatments for gastro-oesophageal reflux disease? A best evidence topic. Int J Surg 2016;30:19-24.
15. Aiolfi A, Asti E, Bernardi D, et al. Early results of magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: Systematic review and meta-analysis. Int J Surg 2018;52:82-8.
16. Richter JE, Kumar A, Lipka S, et al. Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis. Gastroenterology 2018;154:1298-1308.e7.
17. Kinsey-Trotman SP, Devitt PG, Bright T, et al. Randomized Trial of Division Versus Nondivision of Short Gastric Vessels During Nissen Fundoplication: 20-Year Outcomes. Ann Surg 2018;268:228-32.
18. Oor JE, Roks DJ, Koetje JH, et al. Randomized clinical trial comparing laparoscopic hiatal hernia repair using sutures versus sutures reinforced with non-absorbable mesh. Surg Endosc 2018;32:4579-89.
19. Löhde EH. Insights from a magnetic resonance imaging-based evaluation of five hiatal hernia patients pre- and postoperatively on heart-mediated peristaltic action for reflux control and clearance: a case report. Laparosc Surg 2022;6:29.
20. Savary M., Miller G. L'œsophage.Manuel et Atlas d'endoscopie. Editions Gassmann SA, Soleure (Suisse), 1977.
21. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996;111:85-92.
22. Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status - historical perspectives and modern developments. Anaesthesia 2019;74:373-9.
23. Bürkner PC. Advanced Bayesian multilevel modeling with the R Package brms. R J 2018;10:395-411.
24. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev 2014;(4):MR000034.
25. Dallemagne B, Kohnen L, Perretta S, et al. Laparoscopic repair of paraesophageal hernia. Long-term follow-up reveals good clinical outcome despite high radiological recurrence rate. Ann Surg 2011;253:291-6.
26. Bello B, Zoccali M, Gullo R, et al. Gastroesophageal reflux disease and antireflux surgery-what is the proper preoperative work-up? J Gastrointest Surg 2013;17:14-20; discussion p. 20.
27. Boys JA, Azadgoli B, Martinez M, et al. Adequacy of EGD Reporting: a Review of 100 Reports from 100 Endoscopists. J Gastrointest Surg 2021;25:1117-23.
28. Kessing BF, Bredenoord AJ, Saleh CM, et al. Effects of anxiety and depression in patients with gastroesophageal

reflux disease. Clin Gastroenterol Hepatol 2015;13:1089-95.e1.
29. Yang XJ, Jiang HM, Hou XH, et al. Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life. World J Gastroenterol 2015;21:4302-9.
30. Visick AH. A study of the failures after gastrectomy. Ann R Coll Surg Engl 1948;3:266-84.
31. Rijnhart-De Jong HG, Draaisma WA, Smout AJ, et al. The Visick score: a good measure for the overall effect of antireflux surgery? Scand J Gastroenterol 2008;43:787-93.
32. Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998;7:75-83.
33. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993;2:217-27.
34. Kulich KR, Malfertheiner P, Madisch A, et al. Psychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease. Health Qual Life Outcomes 2003;1:62.
35. Velanovich V. Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL) quality-of-life scales for gastroesophageal reflux disease. J Gastrointest Surg 1998;2:141-5.
36. Contini S, Scarpignato C. Evaluation of clinical outcome after laparoscopic antireflux surgery in clinical practice: still a controversial issue. Minim Invasive Surg 2011;2011:725472.
37. Jobe BA, Richter JE, Hoppo T, et al. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. J Am Coll Surg 2013;217:586-97.
38. Wiezcorek A. Development of an ex-vivo model of the cardio-oesophageal peristaltic pump. (Aufbau eines ex-vivo Modells zur gastroösophagealen Refluxkrankheit). Institute of Biotechnology, Faculty III, Medical Biotechnology, Technical University Berlin, Germany. Master's thesis 2015:1-86. Available online: https://www.medbt.tu-berlin.de/menue/home
39. Müller-Stich BP, Linke GR, Senft J, et al. Laparoscopic Mesh-augmented Hiatoplasty With Cardiophrenicopexy Versus Laparoscopic Nissen Fundoplication for the Treatment of Gastroesophageal Reflux Disease: A Double-center Randomized Controlled Trial. Ann Surg 2015;262:721-5; discussion 725-7.
40. Sathasivam R, Bussa G, Viswanath Y, et al. 'Mesh hiatal hernioplasty' versus 'suture cruroplasty' in laparoscopic para-oesophageal hernia surgery; a systematic review and meta-analysis. Asian J Surg 2019;42:53-60.
41. Tam V, Winger DG, Nason KS. A systematic review and meta-analysis of mesh vs suture cruroplasty in laparoscopic large hiatal hernia repair. Am J Surg 2016;211:226-38.
42. Watson DI, Jamieson GG, Lally C, et al. Multicenter, prospective, double-blind, randomized trial of laparoscopic nissen vs anterior 90 degrees partial fundoplication. Arch Surg 2004;139:1160-7.
43. Broeders JA, Roks DJ, Ahmed Ali U, et al. Laparoscopic anterior 180-degree versus nissen fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis of randomized clinical trials. Ann Surg 2013;257:850-9.
44. Håkanson BS, Lundell L, Bylund A, et al. Comparison of Laparoscopic 270° Posterior Partial Fundoplication vs Total Fundoplication for the Treatment of Gastroesophageal Reflux Disease: A Randomized Clinical Trial. JAMA Surg 2019;154:479-86.
45. Celasin H, Genc V, Celik SU, et al. Laparoscopic revision surgery for gastroesophageal reflux disease. Medicine (Baltimore) 2017;96:e5779.
46. Grover BT, Kothari SN. Reoperative antireflux surgery. Surg Clin North Am 2015;95:629-40.
47. Neuhauser B, Hinder RA. Laparoscopic reoperation after failed antireflux surgery. Semin Laparosc Surg 2001;8:281-6.
48. Patel NM, Puri A, Sounderajah V, et al. Quality of life and symptom assessment in paraesophageal hernias: a systematic literature review of reporting standards. Dis Esophagus 2021;34:doaa134.
49. Andolfi C, Plana A, Furno S, et al. Paraesophageal Hernia and Reflux Prevention: Is One Fundoplication Better than the Other? World J Surg 2017;41:2573-82.
50. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20; quiz 1943.
51. Yadlapati R, Hungness ES, Pandolfino JE. Complications of Antireflux Surgery. Am J Gastroenterol 2018;113:1137-47.
52. Coakley KM, Groene SA, Colavita PD, et al. Roux-En-Y gastric bypass following failed fundoplication. Surg Endosc 2018;32:3517-24.
53. Awais O, Luketich JD, Schuchert MJ, et al. Reoperative

antireflux surgery for failed fundoplication: an analysis of outcomes in 275 patients. Ann Thorac Surg 2011;92:1083-9; discussion 1089-90.
54. Furnée EJ, Draaisma WA, Broeders IA, et al. Surgical reintervention after failed antireflux surgery: a systematic review of the literature. J Gastrointest Surg 2009;13:1539-49.
55. Huddy JR, Markar SR, Ni MZ, et al. Laparoscopic repair of hiatus hernia: Does mesh type influence outcome? A meta-analysis and European survey study. Surg Endosc 2016;30:5209-21.
56. Stadlhuber RJ, Sherif AE, Mittal SK, et al. Mesh complications after prosthetic reinforcement of hiatal closure: a 28-case series. Surg Endosc 2009;23:1219-26.
57. Li J, Cheng T. Mesh erosion after hiatal hernia repair: the tip of the iceberg? Hernia 2019;23:1243-52.

doi: 10.21037/ls-22-1
Cite this article as: Löhde EH, Thomas F. Results of a prospective, uncontrolled, single-arm study of 1,351 patients with hiatal hernia operated on exclusively with DeltaMesh hiatal reconstruction over a 10-year period. Laparosc Surg 2022;6:22.

Supplementary

Appendix 1

Questionnaires at T0 (preoperatively on admission)

T0
Postoperative Questionnaire
PD Dr. med. Eckhard Löhde
Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement (**LOEHDE**)

1. **If you take your advised medication regularly: do you suffer from the following complaints?**

(Please note: All the time = daily often = 2-3x/week on and off = 1x/week rarely = 1x/month never = does not occur)

1. Do you suffer from **acid reflux** ?
All the time often on and off rarely never

2. Do liquids or foods come back into **your mouth when bending over**?
All the time often on and off rarely never

3. Do you suffer from **pain** in the upper abdomen or chest?
All the time often on and off rarely never

4. Do you suffer from problems while **swallowing**?
All the time often on and off rarely never

5. Do you suffer from **hoarseness, frequent throat clearing, or a stuffy nose** ?
All the time often on and off rarely never

6. Do you suffer from **sore throat**?
All the time often on and off rarely never

7. Do you **feel stuffed or bloated** in the upper abdomen?
All the time often on and off rarely never

8. Do you suffer from **cough attacks at night**?
All the time often on and off rarely never

9. Do you suffer from **frequent air belching**?
All the time often on and off rarely never

10. Do you suffer from a **sick gastric feeling or nausea** ?
All the time often on and off rarely never

11. Do you have to observe a **special diet** to prevent worsening of your complaints ?
All the time often on and off rarely never

12. Do you sleep with **your chest raised**?
All the time often on and off rarely never

13. Do you eat **fast**?
All the time often on and off rarely never

14. Do you feel a **painful pressure** in your chest?
All the time often on and off rarely never

15. Do you have **breathing difficulties** causing **physical restrictions**?
All the time often on and off rarely never

16. Do you suffer from **sudden palpitation or arrhythmia**?
All the time often on and off rarely never

https://dx.doi.org/10.21037/ls-22-1

T0

Preoperative Questionnaire

PD Dr.med.Eckhard Löhde

Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement **(LOEHDE)**

2. **If you take your advised medication: Do you feel intolerance referring to the following food products?**

   (*Please underline all appropriate points)*

   Coffee, sparkling wine, sparkling water, fruit juice, red wine, white wine

   Sweets, cake, chocolate, tomato products

   Others:……..……

   No restrictions

3. **Which medication do you take to ease your complaints?** *(Please underline)*

   .....mg Nexium .....mg Omeprazol .....mg Omep .....mg Pantozol,

   .....mg Rifun .....mg Pariet .....mg Maloxan .....mg Sodium bicarbonate

   Others: …….

4. **If you take your advised medication properly: How do you feel?** (Visick score)

   (Please mark the most appropriate point)

   ☐ = No complaints with my medication

   ☐ = Mild complaints and doctor visits are rare

   ☐ = Moderate complaints and doctor visits are often

   ☐ = No improvement by my medication

5. **How long have you been suffering from the symptoms?**

   ..... years

6. **Because of your complaints, how often did you have the following examinations?**

   ……. Consultation of my doctor

   ……. Gastroscopy

   ……. Coloscopy

   ……. X-ray examination

   ……. MRI or CT scan

   ……. Stress or 24 h EKG

   ……. Intracardiac catheter

   ……. Admission to a hospital for examination

https://dx.doi.org/10.21037/ls-22-1

T0

Preoperative Questionnaire

PD Dr. med. Eckhard Löhde
Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement **(l.oe.h.d.e.)**

7. **If you <u>DO NOT</u> take your advised medication regularly: do you suffer from the following complaints?**

(Please note: All the time=daily often=2-3x/week on and off=1x/week rarely=1x/month never=does not occur)

1. Do you suffer from **acid reflux**?

All the time often on and off rarely never

2. Do **liquid or foods come back into your mouth whenbending over**?

All the time often on and off rarely never

3. Do you suffer from **pain** in the upper abdomen or chest?

All the time often on and off rarely never

4. Do you suffer from problems while **swallowing**?

All the time often on and off rarely never

5. Do you suffer from **hoarseness, frequent throat clearing, or a stuffy nose**?

All the time often on and off rarely never

6. Do you suffer from **sore throat**?

All the time often on and off rarely never

7. Do you **feel stuffed or bloated** in the upper abdomen?

All the time often on and off rarely never

8. Do you suffer from **cough attacks at night**?

All the time often on and off rarely never

9. Do you suffer from **frequent air belching**?

All the time often on and off rarely never

10. Do you suffer from a **sick gastric feeling or nausea**?

All the time often on and off rarely never

11. Do you have to observe **a special diet** to prevent worsening of your complaints?

All the time often on and off rarely never

12. Do you sleep with your **chest raised**?

All the time often on and off rarely never

13. Do you eat **fast**?

All the time often on and off rarely never

14. Do you feel a **painful pressure** in your chest?

All the time often on and off rarely never

15. Do you have **breathing difficulties** and **physical restrictions**?

All the time often on and off rarely never

16. Do you suffer from **sudden palpitation or arrhythmia**?

All the time often on and off rarely never

https://dx.doi.org/10.21037/ls-22-1

T0

Preoperative Questionnaire

PD Dr.med.Eckhard Löhde

Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement **(l.oe.h.d.e.)**

8. **NOW: If you DO NOT take your advised medication:**

   Would you feel intolerance referring to the following food products?

   (*Please underline all appropriate points)*

   Coffee, sparkling wine, sparkling water, fruit juice, red wine, white wine

   Sweets, cake, chocolate, tomato products

   Others:……..……

   No restrictions

9. **What were your doctors' suggestions?** *(Please mark all appropriate points)*

   □ Continue medication!
   □ Increase the dosage!
   □ Change your medication!
   □ Change your daily habits!
   □ Try a special diet!
   □ Consider an operation!
   □ **Don´t** go for an operation!

   Others: …….

10. **What are the worst of your complaints**?

……

……

11. **Were you a premature baby or twin?** □ Yes □ No
12. **Do you have spinal scoliosis or a torsion?** □ Yes □ No
13. **Are there other members in your family suffering from reflux?** □ Yes □ No
    (children, father, mother, uncle, grandparents)

    If Yes: **Who?**.....

Thank you very much for accurately answering the questions!

Dr. med. Eckhard Löhde

https://dx.doi.org/10.21037/ls-22-1

Appendix 2

Questionnaires at T1 (1 year postoperatively)

T1
Postoperative Questionnaire
PD Dr. med. Eckhard Löhde
Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement **(LOEHDE)**

1. **One year after the LOEHDE procedure: do you suffer from the following complaints?**

(Please note: All the time=daily often=2-3x/week on and off=1x/week rarely=1x/month never=does not occur)

1. Do you suffer from **acid reflux**?
All the time often on and off rarely never

2. Do liquids or foods come back into **your mouth when bending over**?
All the time often on and off rarely never

3. Do you suffer from **pain** in the upper abdomen or chest?
All the time often on and off rarely never

4. Do you suffer from problems while **swallowing**?
All the time often on and off rarely never

5. Do you suffer from **hoarseness, frequent throat clearing, or a stuffy nose**?
All the time often on and off rarely never

6. Do you suffer from **sore throat**?
All the time often on and off rarely never

7. Do you **feel stuffed or bloated** in the upper abdomen?
All the time often on and off rarely never

8. Do you suffer from **cough attacks** at night?
All the time often on and off rarely never

9. Do you suffer from **frequent air belching**?
All the time often on and off rarely never

10. Do you suffer from a **sick gastric feeling or nausea**?
All the time often on and off rarely never

11. Do you have to observe a **special diet** to prevent worsening of your complaints?
All the time often on and off rarely never

12. Do you sleep with your **chest raised?**
All the time often on and off rarely never

13. Do you eat **fast**?
All the time often on and off rarely never

14. Do you feel a **painful pressure** in your chest?
All the time often on and off rarely never

15. Do you have **breathing difficulties** causing **physical restrictions**?
All the time often on and off rarely never

16. Do you suffer from **sudden palpitation or arrhythmia**?
All the time often on and off rarely never

https://dx.doi.org/10.21037/ls-22-1

T1

Postoperative Questionnaire

PD Dr. med. Eckhard Löhde

Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement **(LOEHDE)**

2. **Do you feel intolerance referring to the following food products?**
   (*Please underline all appropriate points)*

   Coffee, sparkling wine, sparkling water, fruit juice, red wine, white wine

   Sweets, cake, chocolate, tomato products

   Others:……..……

   No restrictions

3. As to your quality of life (QoL) referring to daily life, nourishment, sports, mood, and so forth.
   To which answer would you agree most likely? *(Please mark the most appropriate point)*

   ☐ = Yes, my QoL is much better at any rate. I am so glad about it.

   ☐ = Yes, my QoL is better. I am satisfied.

   ☐ = No, my QoL has not changed very much. I am not really satisfied.

   ☐ = No, my QoL is even worse. I am disappointed.

4. **How long did it take to recover after the surgery?**

   ..... weeks

5. **Which were your complaints in the first few weeks after the surgery?**

…….

…….

…….

6. **Would you choose the LOEHDE procedure again to treat your complaints retrospectively?**
   (Please mark the appropriate point)

   ☐ = **Definitely**

   ☐ = Probably yes

   ☐ = Probably no

   ☐ = No, certainly no!

https://dx.doi.org/10.21037/ls-22-1

T1

Postoperative Questionnaire

PD Dr. med. Eckhard Löhde

Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement **(LOEHDE)**

7. **From today's point of your experience: How would you score the different therapies?**

(School grading: 1=very good 2=good 3=satisfying 4=sufficient 5=inadequate)

Medical treatment (PPI medication) Score ( )

Operative treatment (LOEHDE procedure) Score ( )

8. **How do you feel now after surgery referring to your former complaints?**

(Please mark the most appropriate point) (Visick score)

☐ = No complaints

☐ = Mild complaints and doctor visits are rare

☐ = Moderate complaints and doctor visits are often

☐ = No improvement by the operation

9. **Important! Did you have relevant problems related to the hiatal hernia surgery?**

(Please mark all appropriate points and do not hesitate to contact the team at any time!)

I had to contact my doctor	☐ Yes ☐ No
I had a gastroscopy	☐ Yes ☐ No
I have to take PPI medication again!	☐ Yes ☐ No
I had another hiatal hernia operation	☐ Yes ☐ No

What kind of problems emerged?

…….

…….

10. **Do you have any notes, thoughts, or recommendations? Do you wish to have the doctors contact?**

Please write down freely!

…….

…….

Thank you very much for accurately answering the questions!

https://dx.doi.org/10.21037/ls-22-1

Appendix 3

Questionnaires at T5 (5 years postoperatively)

T5
Postoperative Questionnaire
PD Dr. med. Eckhard Löhde
Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement (**LOEHDE**)

1. **Five years after the LOEHDE procedure: do you suffer from the following complaints?**

(Please note: All the time=daily often=2-3x/week on and off=1x/week rarely=1x/month never=does not occur)

1. Do you suffer from **acid reflux**?
All the time often on and off rarely never

2. Do liquids or foods come back into **your mouth when bending over**?
All the time often on and off rarely never

3. Do you suffer from **pain** in the upper abdomen or chest?
All the time often on and off rarely never

4. Do you suffer from problems while **swallowing**?
All the time often on and off rarely never

5. Do you suffer from **hoarseness, frequent throat clearing, or a stuffy nose**?
All the time often on and off rarely never

6. Do you suffer from **sore throat**?
All the time often on and off rarely never

7. Do you **feel stuffed or bloated** in the upper abdomen?
All the time often on and off rarely never

8. Do you suffer from **cough attacks** at night?
All the time often on and off rarely never

9. Do you suffer from **frequent air belching**?
All the time often on and off rarely never

10. Do you suffer from a **sick gastric feeling or nausea**?
All the time often on and off rarely never

11. Do you have to observe a **special diet** to prevent worsening of your complaints?
All the time often on and off rarely never

12. Do you sleep with your **chest raised**?
All the time often on and off rarely never

13. Do you eat **fast**?
All the time often on and off rarely never

14. Do you feel a **painful pressure** in your chest?
All the time often on and off rarely never

15. Do you have **breathing difficulties** causing **physical restrictions**?
All the time often on and off rarely never

16. Do you suffer from **sudden palpitation or arrhythmia**?
All the time often on and off rarely never

https://dx.doi.org/10.21037/ls-22-1

T5

Postoperative Questionnaire

PD Dr. med. Eckhard Löhde

Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement **(LOEHDE)**

2. **Do you feel intolerance referring to the following food products?**

(*Please underline all appropriate points)*

Coffee, sparkling wine, sparkling water, fruit juice, red wine, white wine

Sweets, cake, chocolate, tomato products

Others:……..……

No restrictions

3. As to your quality of life (QoL) referring to daily life, nourishment, sports, mood and so forth.

To which answer would you agree most likely? *(Please mark the most appropriate point)*

☐ = Yes, my QoL is much better at any rate. I am so glad about it.

☐ = Yes, my QoL is better. I am satisfied.

☐ = No, my QoL has not changed very much. I am not really satisfied.

☐ = No, my QoL is even worse. I am disappointed.

4. **Would you choose the LOEHDE procedure again to treat your complaints retrospectively?**

(Please mark the appropriate point)

☐ = **Definitely**

☐ = Probably yes

☐ = Probably not

☐ = No, certainly not!

5. **How would you score the different therapies retrospectively?**

(School grading: 1=very good 2=good 3=satisfying 4=sufficient 5=inadequate)

Medical treatment (PPI medication) Score ( )

Operative treatment (LOEHDE procedure) Score ( )

https://dx.doi.org/10.21037/ls-22-1

T5

Postoperative Questionnaire

PD Dr. med. Eckhard Löhde

Laparoscopic.**oe**sophago.**h**iatal.**d**eltamesh.**e**nforcement **(LOEHDE)**

6. **How do you feel now after surgeryreferring to your former complaints?**

(Please mark the most appropriate point) (Visick score)

- ☐ = No complaints
- ☐ = Mild complaints and doctor visits are rare
- ☐ = Moderate complaints and doctor visits are often
- ☐ = No improvement by the operation

7. **Important! Did you have relevant problems related to the hiatal hernia surgery?**

(Please mark all appropriate points and do not hesitate to contact the team at any time!)

I had to contact my doctor	☐ Yes ☐ No
I had a gastroscopy	☐ Yes ☐ No
I have to take PPI medication again!	☐ Yes ☐ No
I had another hiatal hernia operation	☐ Yes ☐ No

What kind of problems emerged?

……

……

8. **Do you have any notes, thoughts, or recommendations? Do you wish to have the doctors contact?**

Please write down freely!

……

……

Thank you very much for accurately answering the questions!

Dr. med.Eckhard Löhde

https://dx.doi.org/10.21037/ls-22-1



Figure S1 Symptom scores split into proportions of scoring values. Proportions confirm that without PPI medication (T0Med–) patients report a wide range of complaints occurring daily and during a week (Predominant scores 1–2). PPI treatment (T0Med+) shows an alleviating effect, especially for heartburn, but many complaints persist (Predominant scores 2–3). Cure of patients is only achieved at T1 and T5, as symptom scores predominantly improve to 3–4.

Symptom score: 0 = all the time (daily); 1 = often (2–3x/week); 2 = on and off (1x/week); 3 = rarely (1x/month); 4 = never (does not occur); NA = not available. T0Med– = preoperative without PPI; T0Med+ = preoperative with PPI; T1= 1 year postoperatively; T5 = 5 years postoperatively.

Table S1 Symptom score frequencies

Observation point	Frequency total	Missing data	Valid total
T0Med+	n=1351	n=59	n=1292 (100%)
T1	n=1351	n=424	n=927 (100%)
T5	n=1351	n =1151	n=200 (100%)

Valid total values were used to describe frequencies and proportions of symptoms such as such heartburn, volume reflux, cough attacks at night, hoarseness, sore throat, belching, bloating, nausea, dysphagia, chest pain, palpitation, and dyspnoea. T0Med– = preoperative without PPI; T0Med+ = preoperative with PPI; T1= 1 year postoperatively; T5 = 5 years postoperatively. To note: Due to the end of the study after 10 years, the observation point T1 could only be reached by 1287/1351 patients and observation point T5 by 529/1351 patients.

https://dx.doi.org/10.21037/ls-22-1

Table S2 Food intolerance frequencies

Observation point	Frequency total	Missing data	Valid total
T0Med–	n =1351	n=192	n=1159 (100%)
T0Med+	n=1351	n=50	n=1301 (100%)
T1	n=1351	n=484	n=867 (100%)
T5	n=1351	n =1151	n=200 (100%)

Valid total values were used to describe frequencies and proportions of food intolerances for critical drinks such as white wine, sparkling wine, red wine, fizzy drinks, fruit juices, and coffee, as well as food such as sweets, cakes, chocolate, and tomatoes. T0Med– = preoperative without PPI; T0Med+ = preoperative with PPI; T1= 1 year postoperatively; T5 = 5 years postoperatively. To note: Due to the end of the study after 10 years, the observation point T1 could only be reached by 1287/1351 patients and observation point T5 by 529/1351 patients.



Figure S2 Visick scores split into proportions of scoring values. Proportions confirm that despite optimised PPI medication at T0Med+, almost no patient felt cured preoperatively and continued doctor visits were required. The Visick score that best described the state of health was III. Postoperatively, at T1 and T5, patients predominantly attributed their condition to Visick score I–II. Visick score: I = no complaints; II = mild complaints relieved by care and doctor visits are rare; III = moderate complaints not relieved by care and doctor visits are often; IV = no improvement. NA = not available. T0Med+ = preoperative with PPI; T1 = 1 year postoperatively; T5 = 5 years postoperatively.

https://dx.doi.org/10.21037/ls-22-1

Table S3 Visick score frequencies

Observation point	Frequency total	Missing data	Valid total	Visick I	Visick II	Visick III	Visick IV
T0Med+	n=1351	n=50	n=1301 (100%)	n=9 (0.7%)	n=322 (24,8%)	n=760 (58,4%)	n=210 (16,1%)
T1	n=1351	n=431	n=920 (100%)	n=364 (39,6%)	n=446 (48,5%)	n=82 (8,9%)	n=28 (3%)
T5	n=1351	n =1151	n=198 (100%)	n=98 (49,5%)	n=90 (45,4%)	n=10 (5%)	n=0 (0%)

Valid total values were used to describe frequencies and proportions of the Visick score. T0Med+ = preoperative with PPI; T1 = 1 year postoperatively; T5 = 5 years postoperatively.

Visick score: I = no complaints; II = mild complaints relieved by care and doctor visits are rare; III = moderate complaints not relieved by care and doctor visits are often; IV = no improvement. To note: Due to the end of the study after 10 years, the observation point T1 could only be reached by 1287/1351 patients and observation point T5 by 529/1351 patients.



Figure S3 Patient ratings of therapeutic efficacy split into proportions of scoring values retrospectively. Retrospective evaluation of the therapeutic efficacy at T1 and T5. PPI medication was inversely assessed in favour of LOEHDE. Rating score: 1 = excellent; 2 = good; 3 = satisfying; 4 = sufficient; and 5 = poor; NA = not available. T1 = 1 year postoperatively; T5 = 5 years postoperatively.

Table S4 Patient rating frequencies

Treatment	Frequency total	Missing data	Valid total	Score 1	Score 2	Score 3	Score 4	Score 5
T1 PPI med.	n=1351	n=506	n=845 (100%)	n=17 (2%)	n=23 (2,7%)	n=73 (8,6%)	n=202 (23,9%)	n=530 (62,7%)
T5 PPI med.	n=1351	n=1166	n=185 (100%)	n=4 (2,2%)	n=7 (3,8%)	n=15 (8,1%)	n=40 (21,6%)	n=119 (64,3%)
T1 LOEHDE	n=1351	n=449	n=902 (100%)	n=610 (67,6%)	n=193 (21,3%)	n=57 (6,3%)	n=20 (2,2%)	n=22 (2,4%)
T5 LOEHDE	n=1351	n=1158	n=193 (100%)	n=142 (73,6%)	n=36 (18,6%)	n=7 (3,6%)	n=5 (2,6%)	n=3 (1,5%)

Valid total values were used to describe frequencies and proportions of the patient ratings. Patient rating: 1 = excellent; 2 = good; 3 = satisfying; 4 = sufficient; and 5 = poor. T1 = 1 year postoperatively; T5 = 5 years postoperatively. To note: Due to the end of the study after 10 years, the observation point T1 could only be reached by 1287/1351 patients and observation point T5 by 529/1351 patients.

https://dx.doi.org/10.21037/ls-22-1

Appendix 4

Delta Mesh background and Technical notes

Introduction

Stable hiatal reconstruction is mandatory for successful hiatal hernia surgery. However, postoperative stability is challenged by significant axial- and bilateral-acting tensile forces, tender and vulnerable muscles without fascial envelopes, and variations of the specific three-dimensional angular composition of the esophageal hiatus in the sagittal and frontal planes. Various techniques of onlay-mesh application have not shown a transparent breakthrough compared to conventional hiatal hernia surgery.

These results led to a fundamentally new closure concept that does not aim to cover the defect, but to induce stable internal reinforcement of the crura. Therefore, a new type of mesh was developed that is specifically adapted to the three-dimensional anatomy of the hiatus and its specific functional requirements.

Innovation

The underlying principle of the DM is the anatomical and functional reconstruction of the disrupted esophageal hiatal unit against the background of its crucial importance for CODIS. Central requirements for the DM were avoidance of an intra-abdominal position, exclusive contact only with the targeted crura, muscle shielding from adjacent abdominal organs, induction of a stable three-dimensional muscle-mesh complex, constructional resistance to the prevailing axial and bilateral tensile forces, safe and easy mesh fixation, small size and simple handling in laparoscopic procedures.

Results

Shape and material

The DM is V-shaped, 30x40x11 mm in size. It is based on the three-dimensional principle of a T-profile, which creates two longitudinal compartments for stable embedding of the left and right crus. This creates a three-dimensional, bi-angular adhesion system with an enlarged integration surface for the muscle tissue. The DM is made of polyvinylidene fluoride, which best matches the natural consistency of the crura and facilitates surgical adjustment to the individual anatomy.

Centrefold

The centerfold arises vertically along the longitudinal midline of the wings and determines the decisive three-dimensional structure of the DM. It creates the two compartments of the T-profile for comprehensive muscle embedding and provides an active edge-to-edge interlocking of the crura. The DM height is limited to 11 mm, which thus allows for complete coverage by the crura. The centerfold supports the longitudinal and torsional stability of the DM and always ensures its standardized exact concentric positioning in the hiatal midline.

Bilateral wings

Both wings unfold autonomously retrocrurally due to the construction and elasticity of the DM. They have a maximum width of 30 mm at the base to provide intensive muscle integration in this area of maximum axial and bilateral tensile forces and to create a stable retrocrural back shield to protect the crura from the transecting forces of the straining hiatal sutures. As the tensile forces in the hiatus decrease towards the posterior, the DM can taper towards the tip without losing stability. The resulting delta shape of the DM significantly facilitates retrocrural positioning of the wings behind the crura.

Location

The DM is placed in the widened esophageal hiatus, inverted, with the base up and the tip down directly below the esophagus. When the threaded first hiatal suture is closed, the DM is automatically positioned concentrically, covered by both crura and shielded from the abdominal cavity.

Fixation

The DM fixation and hiatal closure are simultaneously achieved by the reverse closure technique. The crucial first suture (0-Prolene 0.9m, CT-2 Plus; PROLENE™, Ethicon® Endo-Surgery Inc., USA) takes 8–10 mm of the left crus directly below the esophagus, is threaded extracorporeally along the DM base, and after insertion of the DM through an 11 mm trocar, the right crus is correspondingly grasped in a horizontal line. Closure is performed with a tight locking suture in the extracorporeal technique under tension. This first suture neutralizes all bilaterally acting forces. Therefore, all other 1-2 sutures further below only capture both crura and the base of the centerfold and provide the final closure of the hiatal defect. Additional fixation is not required.

Discussion

Onlay-mesh techniques in common hernia surgery focus on the simple but successful approach to cover a defect by an attached flat mesh. However, these techniques require a large mesh-tissue contact area, reliable structures for mesh fixation, the absence of sensitive adjacent hollow organs and predominant axial instead of bilateral tensile forces. All those prepositions are absent in the hiatal area. In particular, hiatal hernia repair is not about somehow closing a defect,

https://dx.doi.org/10.21037/ls-22-1



Figure S4 Comparison of hiatal closure concepts. (A) Despite the hiatal coverage by an intraabdominal onlay-mesh, axial force vectors ① continuously strain the sutures between the crura (C) and bilateral forces ② additionally pull the muscles apart underneath the mesh. (B) In DeltaMesh implantation the axial forces support the firm pressing of the crura into its retroabdominal compartments and the bilateral forces are resisted by the edge-to-edge integration of the crura with the centrefold.

but about restoring a fundamental functional structure that is part of the interacting organ system CODIS.

Therefore, the specific architecture of the hiatus was transferred to a corresponding three-dimensional composition of the DM, matching the requirements of inner hiatal enhancement. The T-profile is designed to activate stable edge-to-edge interlocking of the crura and to achieve high joint stability in a bi-angular fusion system. These constructional advantages exceed the stability of common single-angular systems with flat, surface-covering onlay-meshes (*Figure S4*).

Due to its retrocrural position, the DM is shielded from abdominal organs and contact is focused almost exclusively on the targeted crura. Despite its small size, the three-dimensional structure seems to provide sufficient surface area for deep muscle integration.

The easy handling of the DM is based on the small size, elasticity, and ease of grasping the centerfold for positioning. Fast and reliable DM anchoring is obtained by integration into the regular sutures of the hiatoplasty, thus providing a time-saving simplification in laparoscopic procedures. The DM construction and the reverse closure technique ensure that the centerfold is always exactly in the intercrural midline after closure and both wings are retrocrurally unfolded, regardless of hernia size, tissue quality, or surgical variations.

The DM length is intraoperatively adjusted to the size of the defect. The reverse closure technique neutralizes all tensile forces already by the first suture. Therefore, all further sutures can be positioned quickly, tension-free and at a wide distance. This not only saves time, but also helps to preserve the crucial blood supply to the crura. The developed proportions of the DM are suitable for the vast majority of hiatal hernia patients. However, a ready-made DM in different sizes and design could be an important option in the future and may expand indication for the three-dimensional closure technique of i.e. incisional hernias.

The DM concept seems to eliminate various disadvantages of common two-dimensional onlay meshes as the great variability in terms of size, shape, type, placement, fixation, and surgical assessment. Furthermore, during laparoscopic positioning of a flat onlay-mesh, the diaphragm is straightened and stretched by the CO2 pressure. However, CO_2 venting inevitably causes the diaphragm to fall back to its normal anatomical angles, leading to uncontrolled folding of the fixed onlay mesh with the risk of undefined mesh-tissue adhesion complexes found at recurrency surgery.

Conclusions

The new three-dimensional DM provides the stable bi-angular crura closure for hiatal hernia patients. The newly described technique of reverse closure is simple, time-saving, and integrates cruroplasty and DM fixation without the need for additional sutures. The three-dimensional DM closure concept is standardized, reproducible, and independent of the shape or size of the hiatal hernia.

https://dx.doi.org/10.21037/ls-22-1